Severe Acute Respiratory-Syndrome Treatment Global Market Report 2024

Description

“Severe Acute Respiratory-Syndrome Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on severe acute respiratory-syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for severe acute respiratory-syndrome treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The severe acute respiratory-syndrome treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Class: Antibiotics; Antiviral; Corticosteroids; Monoclonal Antibodies; Other Drug Classes
2) By Route Of Administration: Oral; Intravenous
3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV); Severe Acute Respiratory Syndrome COVID-19 2 (SARS-CoV-2)
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Merck And Co Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Severe acute respiratory syndrome (SARS) is a severe type of pneumonia caused by an airborne virus that can be transmitted through tiny droplets of saliva. This previously unidentified virus belongs to the Coronaviridae family and is known as SARS-associated COVID-19 (SARS-CoV). The treatment for severe acute respiratory syndrome (SARS) involves medical interventions and supportive measures aimed at managing the symptoms and complications of this viral respiratory illness.

The primary classes of drugs used in the treatment of severe acute respiratory syndrome include antibiotics, antivirals, corticosteroids, monoclonal antibodies, and others. Antibiotics are a class of medications used to treat bacterial infections. They function by either killing bacteria or inhibiting their growth, depending on the specific type of antibiotic. In the context of severe acute respiratory syndrome caused by SARS-CoV and SARS-CoV-2, these antibiotics are administered orally and intravenously. They are distributed through various channels, including hospital pharmacies and retail pharmacies, among others.

The severe acute respiratory syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides severe acute respiratory-syndrome treatment market statistics, including severe acute respiratory-syndrome treatment industry global market size, regional shares, competitors with a severe acute respiratory syndrome treatment market share, detailed severe acute respiratory-syndrome treatment market segments, market trends and opportunities and any further data you may need to thrive in the severe acute respiratory-syndrome treatment industry. This severe acute respiratory-syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The severe acute respiratory-syndrome treatment market size has grown rapidly in recent years. It will grow from $2.99 billion in 2023 to $3.45 billion in 2024 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to global outbreak response, antiviral drug development, vaccine development, public health preparedness.

The severe acute respiratory-syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $6.12 billion in 2028 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to broad-spectrum antivirals, emerging therapeutics, vaccine advancements, pandemic preparedness. Major trends in the forecast period include rna-targeted therapies, ai in drug discovery, global collaborations, public health education.

The increasing prevalence of respiratory diseases is anticipated to be a driving force behind the growth of the severe acute respiratory syndrome treatment market in the foreseeable future. Respiratory diseases encompass a spectrum of medical conditions that affect the respiratory system, responsible for functions such as breathing and gas exchange with the external environment. In the context of respiratory diseases, severe acute respiratory syndrome treatments are instrumental in alleviating symptoms, preventing respiratory failure, mitigating inflammation, and sustaining optimal oxygen levels. For instance, recent data from the Australian Institute of Health and Welfare, a national agency based in Australia, revealed a notable upsurge in respiratory disease-related deaths, rising from 43,031 in 2020 to 46,551 in 2021 in Australia. Thus, the increasing incidence of respiratory diseases is the driving force propelling the expansion of the severe acute respiratory syndrome treatment market.

The progressive surge in investments in research and development is poised to be a catalyst for the growth of the severe acute respiratory syndrome treatment market in the near future. These investments in research and development, often abbreviated as R&D, pertain to the allocation of financial resources and human expertise by organizations, governments, or entities with the aim of conducting systematic and innovative investigations and initiatives, with the goal of unearthing fresh knowledge. Augmented R&D investments play a pivotal role in advancing the array of available treatment options for severe acute respiratory syndromes, including conditions like SARS and COVID-19. Such investments contribute to the formulation of effective drugs, vaccines, diagnostic tools, and therapeutic strategies, ultimately enhancing patient outcomes and reinforcing global health preparedness. Notably, in August 2023, the United States Department of Health and Human Services, the executive branch department of the U.S. federal government, disclosed that the U.S. Department of Health and Human Services (HHS), in collaboration with the Administration for Strategic Preparedness and Response (ASPR), had allocated over $1.4 billion for Project NextGen. This initiative aims to support the development of the next generation of COVID-19 vaccines and treatments. Consequently, the increasing investments in research and development are the pivotal driving force behind the growth of the severe acute respiratory syndrome treatment market.

The growth of the severe acute respiratory syndrome treatment market during the forecast period is hampered by the presence of limited treatment options. The constraints of limited treatment options for severe acute respiratory syndrome can lead to challenges in effectively managing patients, resulting in delayed recovery, increased mortality rates, heightened strain on healthcare systems, and significant economic and global health repercussions. For example, as of October 2021, despite extensive global efforts, an effective treatment for severe acute respiratory syndrome (SARS) had not yet been identified, as reported by the Mayo Foundation for Medical Education and Research (MFMER), a non-profit organization. Traditional antibiotics are ineffective against viral infections, and the effectiveness of antiviral drugs in addressing this condition has remained restricted. Consequently, the restricted treatment options pose a hindrance to the growth of the severe acute respiratory syndrome treatment market.

Leading companies actively participating in the severe acute respiratory syndrome treatment market are at the forefront of introducing innovative techniques, with a notable example being multiplexed real-time PCR. Multiplexed real-time PCR is a molecular biology technology that facilitates the simultaneous amplification and detection of multiple DNA or RNA targets in a single procedure. A case in point is the product launched by TransGen Biotech Co. Ltd., a Beijing-based manufacturer and researcher of molecular and cellular biology products, in July 2022. They introduced the Trans-SARS-CoV-2, Influenza A and B, and Respiratory Syncytial Virus Assay. This groundbreaking assay is designed as a multiplexed real-time PCR (polymerase chain reaction) assay, capable of detecting and distinguishing severe acute respiratory syndrome COVID-19 2 (SARS-CoV-2), Influenza A, Influenza B, and respiratory syncytial virus (RSV) in a single specimen. This innovative tool plays a crucial role in the diagnosis and treatment of severe acute respiratory syndromes, including COVID-19, influenza, and RSV, thus aiding in guiding treatment decisions and preventing the spread of these diseases.

In March 2022, AbbVie Inc., a U.S.-based pharmaceutical company, established a collaboration with Scripps Research, an independent, non-profit biomedical research and drug discovery institute also based in the United States. This strategic partnership is geared toward the development of cutting-edge direct-acting antiviral therapies designed for the treatment of COVID-19. The collaboration aims to pioneer innovative solutions for combatting the virus.

Major players in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline plc, AstraZeneca plc, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.

North America was the largest region in the severe acute respiratory syndrome treatment market in 2023. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in severe acute respiratory syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the severe acute respiratory syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The severe acute respiratory syndrome treatment market consists of revenues earned by entities by providing services such as respiratory therapy, oxygen therapy, ventilation, intensive care, isolation and infection control, fluid and electrolyte management and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The severe acute respiratory syndrome treatment market also includes sales of azithromycin, immunomodulators, vaccines, ribavirin, ritonavir, remdesivir, methylprednisolone, prednisolone, dexamethasone and interferon. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12373

1. Executive Summary

2. Severe Acute Respiratory-Syndrome Treatment Market Characteristics

3. Severe Acute Respiratory-Syndrome Treatment Market Trends And Strategies

4. Severe Acute Respiratory-Syndrome Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Severe Acute Respiratory-Syndrome Treatment Market Size and Growth

5.1. Global Severe Acute Respiratory-Syndrome Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Severe Acute Respiratory-Syndrome Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Severe Acute Respiratory-Syndrome Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Severe Acute Respiratory-Syndrome Treatment Market Segmentation

6.1. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Antibiotics
Antiviral
Corticosteroids
Monoclonal Antibodies
Other Drug Classes
6.2. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Intravenous
6.3. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
6.4. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels

7. Severe Acute Respiratory-Syndrome Treatment Market Regional And Country Analysis

7.1. Global Severe Acute Respiratory-Syndrome Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Severe Acute Respiratory-Syndrome Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market

8.1. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Severe Acute Respiratory-Syndrome Treatment Market

9.1. China Severe Acute Respiratory-Syndrome Treatment Market Overview
9.2. China Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Severe Acute Respiratory-Syndrome Treatment Market

10.1. India Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Severe Acute Respiratory-Syndrome Treatment Market

11.1. Japan Severe Acute Respiratory-Syndrome Treatment Market Overview
11.2. Japan Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Severe Acute Respiratory-Syndrome Treatment Market

12.1. Australia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Severe Acute Respiratory-Syndrome Treatment Market

13.1. Indonesia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Severe Acute Respiratory-Syndrome Treatment Market

14.1. South Korea Severe Acute Respiratory-Syndrome Treatment Market Overview
14.2. South Korea Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Severe Acute Respiratory-Syndrome Treatment Market

15.1. Western Europe Severe Acute Respiratory-Syndrome Treatment Market Overview
15.2. Western Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Severe Acute Respiratory-Syndrome Treatment Market

16.1. UK Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Severe Acute Respiratory-Syndrome Treatment Market

17.1. Germany Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Severe Acute Respiratory-Syndrome Treatment Market

18.1. France Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Severe Acute Respiratory-Syndrome Treatment Market

19.1. Italy Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Severe Acute Respiratory-Syndrome Treatment Market

20.1. Spain Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market

21.1. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market Overview
21.2. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Severe Acute Respiratory-Syndrome Treatment Market

22.1. Russia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Severe Acute Respiratory-Syndrome Treatment Market

23.1. North America Severe Acute Respiratory-Syndrome Treatment Market Overview
23.2. North America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Severe Acute Respiratory-Syndrome Treatment Market

24.1. USA Severe Acute Respiratory-Syndrome Treatment Market Overview
24.2. USA Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Severe Acute Respiratory-Syndrome Treatment Market

25.1. Canada Severe Acute Respiratory-Syndrome Treatment Market Overview
25.2. Canada Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Severe Acute Respiratory-Syndrome Treatment Market

26.1. South America Severe Acute Respiratory-Syndrome Treatment Market Overview
26.2. South America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Severe Acute Respiratory-Syndrome Treatment Market

27.1. Brazil Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Severe Acute Respiratory-Syndrome Treatment Market

28.1. Middle East Severe Acute Respiratory-Syndrome Treatment Market Overview
28.2. Middle East Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Severe Acute Respiratory-Syndrome Treatment Market

29.1. Africa Severe Acute Respiratory-Syndrome Treatment Market Overview
29.2. Africa Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Severe Acute Respiratory-Syndrome Treatment Market Competitive Landscape And Company Profiles

30.1. Severe Acute Respiratory-Syndrome Treatment Market Competitive Landscape
30.2. Severe Acute Respiratory-Syndrome Treatment Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche Ltd.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. AbbVie Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Merck And Co Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Severe Acute Respiratory-Syndrome Treatment Market Other Major And Innovative Companies

31.1. Bristol Myers Squib company
31.2. GlaxoSmithKline plc
31.3. AstraZeneca plc
31.4. Sanofi SA
31.5. Eli Lilly And Company
31.6. Gilead Sciences Inc.
31.7. Amgen Inc.
31.8. Johnson And Johnson Private Limited
31.9. Moderna Inc.
31.10. Regeneron Pharmaceuticals Inc.
31.11. Hetero labs Ltd.
31.12. Alexion Pharmaceuticals Inc.
31.13. Cadila healthcare Ltd.
31.14. Genentech Inc.
31.15. Cipla Ltd.

32. Global Severe Acute Respiratory-Syndrome Treatment Market Competitive Benchmarking

33. Global Severe Acute Respiratory-Syndrome Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Severe Acute Respiratory-Syndrome Treatment Market

35. Severe Acute Respiratory-Syndrome Treatment Market Future Outlook and Potential Analysis

35.1 Severe Acute Respiratory-Syndrome Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Severe Acute Respiratory-Syndrome Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Severe Acute Respiratory-Syndrome Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer